Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering
Rhea-AI Summary
Autonomix Medical announced the pricing of an underwritten public offering expected to raise $9.0 million in gross proceeds. The offering consists of 1,376,287 common stock units priced at $6.54 per unit. Each unit includes one share of common stock (or pre-funded warrant) and one Series A warrant exercisable at $6.54 with a five-year term. The company granted the underwriter a 45-day option to purchase up to 15% additional shares and warrants. Proceeds will fund clinical trials, research and development, intellectual property development, and working capital. Ladenburg Thalmann & Co. is acting as sole bookrunning manager.
Positive
- Secured $9.0 million in gross funding through public offering
- Warrants have fixed pricing without variable features
- Clear allocation of funds for clinical trials and R&D
Negative
- Potential dilution for existing shareholders
- Additional 15% shares may be issued through underwriter's option
- Offering price represents immediate dilution to current market value
News Market Reaction – AMIX
In the trading session that priced this news, AMIX declined 53.55%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced the pricing of an underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately
The equity offering is comprised of 1,376,287 common stock units (or pre-funded warrant units in lieu of common stock units), priced at a public offering price of
In addition, the Company has granted the underwriter a 45-day option to purchase additional shares of common stock and/or Series A warrants, representing up to
Ladenburg Thalmann & Co. Inc. is acting as the sole bookrunning manager for the offering.
The offering is expected to close on or about November 25, 2024, subject to customary closing conditions.
The Company intends to use the net proceeds from this offering to fund its clinical trial, for other research and development, for development of intellectual property, and for working capital.
The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (No. 333-282940), which was declared effective by the Securities and Exchange Commission (the “SEC”) on November 22, 2024. The offering is being made solely by means of a prospectus. A final prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Electronic copies of the final prospectus may be obtained, when available, from Ladenburg Thalmann & Co. Inc., 640 Fifth Avenue, 4th Floor, New York, New York 10019, or by telephone at (212) 409-2000, or by email at prospectus@ladenburg.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation the satisfaction of customary closing conditions related to the public offering, the completion of the public offering, and the use of the anticipated proceeds from the offering. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on May 31, 2024, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com
